Pathfinders in Biopharma

Biotech has delivered one of its strongest rallies in years, fueled by a resurgence in M&A activity, improving sentiment and continued innovation. But as valuations rise and competition intensifies, investors are becoming increasingly selective. RBC's biotech analysts explore the key drivers behind the rally, the outlook for M&A, the growing role of China and what could determine whether the sector sustains momentum through the second half of the year.Key PointsM&A activity, improving regulatory sentiment and strong clinical data have helped drive a significant re-rating across biotech. Higher valuations have boosted investor confidence but may leave less room for error in the second half. Innovation continues to underpin long-term growth opportunities, although competition is increasing.China's growing role in drug development is reshaping competitive dynamics and business development strategies. Investors are becoming increasingly selective, with a greater focus on company-specific catalysts and fundamentals.Chapter MarkersWhat's driving biotech's rally? [00:52) Brian Abrahams explores the key factors behind biotech's resurgence..Why selectivity matters more now [2:30] Rising valuations have strengthened confidence across biotech, but investors may need to become more discerning about where they allocate capital in the second half.The outlook for biotech M&A [4:02] M&A remains a leading catalyst for biotech investors, with deal activity continuing to shape sentiment and sector performance. What the biotech investor survey revealed [7:11] Lisa Walter discusses investor positioning, valuation expectations and why enthusiasm remains constructive despite a more neutral stance following the rally. Innovation, drug launches and competitive advantage [11:02] Leonid Timashev explores how innovation, commercial execution and emerging modalities are shaping competitive advantage in biotech, and why successful launches remain critical to long-term value creation.China's growing influence in biotech [17:44] China's emergence as a leading source of innovation and business development activity is reshaping competitive dynamics across the biotech sector.What could drive the second half? [20:15] RBC analysts discuss the factors most likely to determine whether biotech can sustain its momentum.

Dyne Therapeutics is an early-stage company gearing up for its first launch, promising to tackle unmet need in patients with neuromuscular disease. President and CEO John Cox outlines the science behind the company’s ambitions, and the expansion efforts that will support its metamorphosis from early-stage company to fully-fledged biotech.Key Points• Dyne Therapeutics is pioneering a new delivery method for its products targeting neuromuscular disease.• With two launches planned, the business is preparing to transform from early-stage company to fully-integrated biotech.• Shared clinical and commercial pathways for Dyne’s primary disease areas allow for capital investment efficiencies.Introductions [00:06]Host Joe Coletti introduces John Cox, President and CEO of Dyne Therapeutics, a clinical-stage biotechnology company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases.Dyne’s journey to commercialization [00:47]Dyne spent 2025 validating its delivery platform. In 2026 it aims to transform itself from an early-stage to a commercial company, with its first product launch scheduled for 2027. Novel drug delivery method [02:09]While most genetic therapies approved for use in the past 10 years have been delivered to the liver, Dyne’s technology is designed to deliver direct to the muscle and the central nervous system.Evidence of effectiveness [03:37]The technology allows for higher-than-typical dosage, but with a favorable safety profile. Trials are showing an improvement in function from baseline for patients with Duchenne muscular dystrophy and myotonic dystrophy.Capabilities and capital investment [06:22]The company is drafting in new capabilities to prepare for product launches. With $900m on the balance sheet, it is well capitalized. Its disease areas share the same clinical and commercial pathways, allowing for efficient capital allocation.

The U.S. administration is keen to sign up more companies to drug pricing deals, and mandatory rules are on the way. But how will the midterm elections affect these and other healthcare policy issues? At RBC’s Global Healthcare Conference, Hunter Hammond and Will Humphrey of Capstone’s healthcare group offered insights on the direction of policy for the rest of the year and beyond. Key PointsMandatory Most Favored Nation pricing rules are likely to be contested in court.The FDA’s initiatives to speed drug development are signals of its modernization intent.The U.S. is more likely to use incentives than sanctions to address mass in-licensing of Chinese innovation.The current program to extend access to GLP-1s could be a template for future breakthrough drugs.Democrat gains in the midterm elections would likely limit further hospital cuts.Introductions [00:08]Host Joe Coletti introduces highlights from the U.S. Healthcare Policy Panel at RBC’s Global Healthcare Conference, featuring Hunter Hammond and Will Humphrey of Capstone’s Healthcare Group. Midterm campaigning [00:40]In the run-up to the midterms, the U.S. administration will aim to focus on messaging about popular policies, such as cutting waste and fraud in Medicare and Medicaid.FDA changes [01:41]After turmoil in the FDA, new leadership is designed to promote stability. Recent moves to speed drug approvals are likely to continue and offer an important signal about FDA modernization. Chinese innovation [04:31]The administration may be uncomfortable with U.S. in-licensing of Chinese technologies, but it is more likely to respond with incentives than any attempt to block the practice.Drug pricing [06:17]Most Favored Nation mandatory pricing models have yet to be finalized and are likely to be challenged in court. Democrats will not support codification of MFN.Democrat priorities [08:08]Democratic gains in the midterms would have the effect of protecting hospitals from further cuts. Reform of 340B is unlikely, however.

This episode of RBC Pathfinders in Biopharma explores how next-generation retinal gene therapies could transform treatment for patients with wet AMD and diabetic macular edema. CCBO of 4D Molecular Therapeutics, Chris Simms, discusses the promise of reducing the burden of frequent injections through long-lasting therapies designed to preserve vision for years. The conversation also examines the firm’s commercial opportunity, global roll-out ambitions, and why sustained retinal care could reshape the future of retina.

Life sciences is a hub of dealmaking activity. Over the past year, more than 30 transactions valued at $1 billion or more have crossed the finish line. But the picture in other segments of healthcare is more mixed. At RBC Capital Markets’ Global Healthcare Conference in New York, Darren Campili, Global Head of Healthcare Investment Banking, hosts colleagues David Levin, Ahmed Attia and Jason Levitz to explore what's driving deals and where the opportunities are heading.Key PointsHealthcare M&A is strong, with a surge of high-value deals in life sciences.Equity performance is challenging, but investors in life sciences and biotech have seen good outcomes.IPO activity has rebounded; again, life sciences and biotech are most successful.Dealmaking has been largely unaffected by regulatory uncertainty, though challenges remain on reimbursement and MFN pricing.Larger companies believe they have the edge in using AI for profitability and competitiveness.Introductions [00:25]Host Darren Campili, Global Head of Healthcare Investment Banking, introduces the podcast and guests: David Levin, Co-Head of U.S. M&A; Ahmed Attia, Managing Director, Healthcare M&A; and Jason Levitz, Head of Healthcare Equity Capital Markets.M&A strength in healthcare [01:11]The M&A market in life sciences is extremely strong. The number of $1 billion-plus deals has tripled in the past year. There has been significant activity among mid-caps as well as large-cap companies, and a diversity of premiums.Healthcare in the equity markets [13:24]In the broader context of the U.S. equity markets, healthcare is performing poorly, particularly among large-cap medtech and services companies. At the same time, life sciences and biotechs are outperforming, leading to diverse outcomes for investors.IPO activity [15:20]IPO volumes have rebounded after some disappointing years. Deal flow has centered on oncology, I&I, and CNS.Political impact [24:15]Dealmaking has continued despite uncertainty over the FDA. Tariff policy has been a net positive for U.S. inflows as pharma businesses seek U.S. capabilities. Managing reimbursement and Most Favored Nation pricing remains challenging for some.